These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 38185772)
1. Ixekizumab versus FAEs and methotrexate in treatment of nail psoriasis in patients with moderate-to-severe psoriasis. Augustin M; Mrowietz U; Willsmann-Theis D; Gerdes S; Fotiou K; Schuster C; Mert C; Holzkaemper T; Behrens F; Pinter A J Dtsch Dermatol Ges; 2024 Feb; 22(2):278-281. PubMed ID: 38185772 [No Abstract] [Full Text] [Related]
2. Nail Psoriasis Does Not Affect Skin Response to Ixekizumab in Patients With Moderate-To-Severe Psoriasis. Rich P; Goldblum O; Disch D; Lin CY; Merola JF; Elewski B J Drugs Dermatol; 2020 Aug; 19(8):741-746. PubMed ID: 32845588 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of ixekizumab on nail psoriasis in paediatric patients with moderate-to-severe psoriasis: a post hoc analysis from IXORA-PEDS. Seyger MMB; Reich A; El Baou C; Schuster C; Riedl E; Paller AS J Eur Acad Dermatol Venereol; 2021 Dec; 35(12):e911-e913. PubMed ID: 34320259 [No Abstract] [Full Text] [Related]
4. Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis. Langley RG; Rich P; Menter A; Krueger G; Goldblum O; Dutronc Y; Zhu B; Wei H; Cameron GS; Heffernan MP J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1763-70. PubMed ID: 25693783 [TBL] [Abstract][Full Text] [Related]
5. Ixekizumab in nail psoriasis. Dattola A; Manfreda V; Mazzilli S; Bianchi L; Giunta A Dermatol Ther; 2020 May; 33(3):e13352. PubMed ID: 32232895 [No Abstract] [Full Text] [Related]
6. Ixekizumab Is Effective in Subjects With Moderate to Severe Plaque Psoriasis With Significant Nail Involvement: Results From UNCOVER 3. Dennehy EB; Zhang L; Amato D; Goldblum O; Rich P J Drugs Dermatol; 2016 Aug; 15(8):958-61. PubMed ID: 27537996 [TBL] [Abstract][Full Text] [Related]
7. Ustekinumab for the treatment of nail psoriasis in heavily treated psoriatic patients. Vitiello M; Tosti A; Abuchar A; Zaiac M; Kerdel FA Int J Dermatol; 2013 Mar; 52(3):358-62. PubMed ID: 23330782 [No Abstract] [Full Text] [Related]
8. Sustained Resolution of Nail Psoriasis Through 5 Years with Ixekizumab: A Post-Hoc analysis from UNCOVER-3. Egeberg A; Kristensen LE; Vender R; Zaheri S; El Baou C; Gallo G; Riedl E; Schuster C Acta Derm Venereol; 2022 Oct; 102():adv00787. PubMed ID: 36121210 [TBL] [Abstract][Full Text] [Related]
9. Successful management of treatment resistant nail psoriasis with tildrakizumab. Simpson K; Low ZM; Howard A; Kern JS Australas J Dermatol; 2021 Aug; 62(3):390-393. PubMed ID: 34114645 [TBL] [Abstract][Full Text] [Related]
10. A 24-week multicentre, randomized, open-label, parallel-group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate-to-severe plaque psoriasis naive to systemic treatment. Reich K; Augustin M; Thaçi D; Pinter A; Leutz A; Henneges C; Schneider E; Schacht A; Dossenbach M; Mrowietz U Br J Dermatol; 2020 Apr; 182(4):869-879. PubMed ID: 31376153 [TBL] [Abstract][Full Text] [Related]
11. Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial. Elewski BE; Okun MM; Papp K; Baker CS; Crowley JJ; Guillet G; Sundaram M; Poulin Y; Gu Y; Geng Z; Williams DA; Rich PA J Am Acad Dermatol; 2018 Jan; 78(1):90-99.e1. PubMed ID: 28993005 [TBL] [Abstract][Full Text] [Related]
12. Effectiveness of systemic treatment agents on psoriatic nails: a comparative study. Demirsoy EO; Kıran R; Salman S; Cağlayan C; Aktürk AS; Bayramgurler D; Bilen N J Drugs Dermatol; 2013 Sep; 12(9):1039-43. PubMed ID: 24002153 [TBL] [Abstract][Full Text] [Related]
13. Small molecule inhibitors and biologics in treating nail psoriasis: A systematic review and network meta-analysis. Huang IH; Wu PC; Yang TH; Li H; Huang YT; Cheng YC; Kuo PH; Lee YH; Huang YC; Tu YK J Am Acad Dermatol; 2021 Jul; 85(1):135-143. PubMed ID: 33482253 [TBL] [Abstract][Full Text] [Related]
15. Nail Psoriasis: An Updated Review and Expert Opinion on Available Treatments, Including Biologics. Bardazzi F; Starace M; Bruni F; Magnano M; Piraccini BM; Alessandrini A Acta Derm Venereol; 2019 May; 99(6):516-523. PubMed ID: 30521057 [TBL] [Abstract][Full Text] [Related]
16. Interventions for nail psoriasis. de Vries AC; Bogaards NA; Hooft L; Velema M; Pasch M; Lebwohl M; Spuls PI Cochrane Database Syst Rev; 2013 Jan; (1):CD007633. PubMed ID: 23440816 [TBL] [Abstract][Full Text] [Related]
17. A case of nail psoriasis-associated psoriatic arthritis successfully treated with adalimumab. Ikumi N; Kitamura N; Shiraiwa H; Inomata H; Nozaki T; Kuwana Y; Matsukawa Y; Hayama T; Sawada S; Takei M; Ochiai T Acta Dermatovenerol Croat; 2014; 22(1):65-6. PubMed ID: 24813847 [No Abstract] [Full Text] [Related]
18. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J). Saeki H; Nakagawa H; Nakajo K; Ishii T; Morisaki Y; Aoki T; Cameron GS; Osuntokun OO; J Dermatol; 2017 Apr; 44(4):355-362. PubMed ID: 27726163 [TBL] [Abstract][Full Text] [Related]
19. Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1. Rich P; Bourcier M; Sofen H; Fakharzadeh S; Wasfi Y; Wang Y; Kerkmann U; Ghislain PD; Poulin Y; Br J Dermatol; 2014 Feb; 170(2):398-407. PubMed ID: 24117389 [TBL] [Abstract][Full Text] [Related]
20. Nail psoriasis: a retrospective study on the effectiveness of systemic treatments (classical and biological therapy). Sánchez-Regaña M; Sola-Ortigosa J; Alsina-Gibert M; Vidal-Fernández M; Umbert-Millet P J Eur Acad Dermatol Venereol; 2011 May; 25(5):579-86. PubMed ID: 21198950 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]